T-knife is creating next-generation T cell therapies for patients with solid tumor cancers. The company's unique approach leverages its MyT platform, a T cell receptor and target identification platform, along with proprietary next-generation enhancements to drive deeper, more durable responses for patients. T-knife is developing a pipeline of TCR-T product candidates; the company's first generation program targeting MAGE-A1 demonstrated safety and POC of the platform in a Phase 1a study. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin. The company has raised nearly $200M to date from leading life sciences investors, and is based in the US and in Germany.